Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (NASDAQ:RLMD), purchased 55,000 shares of the company’s common stock in open market transactions on August 29, 2025. The information comes from a statement provided in a recent SEC filing.
Relmada Therapeutics is a pharmaceutical company incorporated in Nevada and headquartered in Coral Gables, Florida. The company’s common stock trades on the NASDAQ Capital Market under the ticker RLMD.
No additional details regarding the purchase price or the context of the transaction were disclosed in the filing. The company noted that this information was furnished in accordance with Regulation FD Disclosure requirements.
This report is based on a press release statement included in the company’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Relmada Therapeutics announced its second-quarter 2025 earnings, revealing a narrower-than-anticipated loss. The company reported an earnings per share (EPS) of -$0.30, which exceeded analyst expectations of -$0.40. This represents a 25% positive surprise, highlighting improved financial management at Relmada Therapeutics. Despite the earnings surprise, the stock’s after-hours trading showed a modest increase, although specific stock price movements are not the focus here. These developments reflect recent efforts by Relmada Therapeutics to manage its financials more effectively. The earnings results are crucial for investors seeking insights into the company’s financial health. No analyst upgrades or downgrades were reported in the recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.